RCS - vVARDIS AG - Founders Present Drill-Free Early Cavity Treatment
12/01/2026 19:45
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL5936Oa&default-theme=true
RNS Number : 5936O vVARDIS AG 12 January 2026
vVARDIS Founders Present Drill-Free Early Cavity Treatment and Unveil Global
Cavity Awareness Campaign at the 2026 J.P. Morgan Healthcare Conference
vVARDIS founders Drs. Haley and Goly Abivardi share details on oral healthcare
company's remarkable growth trajectory - with over 2 million teeth treated in
24 months - at premiere healthcare investment event
SAN FRANCISCO, CA - January 12, 2026 - vVARDIS
(https://www.vvardis.com/homepage?srsltid=AfmBOop-kEGMO1tYz0kB65ytVaY2xkkfFUNqaifr7Rn7ja23qLYht_qH)
, a Swiss high-growth healthcare company, active in the development of
innovative dental products, today presented its pioneering solution for the
treatment of early cavities, Curodont (https://www.vvardis.com/) ™, at the
2026 J.P. Morgan Healthcare Conference. Founded by dentist-entrepreneur
sisters Drs. Haley and Goly Abivardi, vVARDIS is recognized for its commitment
to advancing the standard of non-invasive dental care through Curodont, its
drill-free solution for dental professionals. The product has experienced
rapid growth and attracted significant investor attention since its launch in
the U.S. market two years ago.
The vVARDIS founders returned to the conference stage after being personally
highlighted by J.P. Morgan CEO Jamie Dimon at the 2025 event- rare in the
conference's history. This recognition highlights vVARDIS' status as an
innovative, disruptive and rapidly growing company in the dental sector.
"Being recognized by Jamie Dimon and invited to return as presenters at the
J.P. Morgan Healthcare Conference is an extraordinary honor-not just for us,
but for the entire field of oral health," said Dr. Haley Abivardi, DMD, co-CEO
and co-founder of vVARDIS. "This platform has amplified our ability to reach
the world's leading healthcare innovators and investors, accelerating our
mission to transform how cavities are treated globally and improve overall
health through better oral health."
During their presentation at the conference, Drs. Haley and Goly Abivardi
showcased vVARDIS as a company founded by dentists and serial dental
entrepreneurs, dedicated to addressing the global burden of cavities as
indicated by the World Health Organization. They highlighted that, prior to
the launch of Curodont™, dental professionals had no non-invasive
restorative treatment option for early-stage cavities; drilling and filling
was the only available approach. Curodont™, vVARDIS' innovative flagship
technology, offers significant benefits to both patients and dental
professionals as a non-invasive, environmentally friendly solution for the
treatment of early-stage cavities. At the presentation, they shared vVARDIS'
ongoing commercial momentum and strong growth metrics, including over 2
million teeth treated in the U.S. alone in 24 months 1 . The presentation
underscored vVARDIS' unique investment proposition, emphasizing the company's
access to a large and growing market, its breakthrough science and proven
clinical results, and the significant commercial momentum achieved in recent
years-making Curodont™ the fastest-growing dental product in its category in
the U.S. 2 .
"Presenting at J.P. Morgan Healthcare marks a turning point for dentistry, as
the connection between oral and overall health is being recognized and
championed by the broader healthcare industry and investors," said Dr. Goly
Abivardi, DMD, co-CEO and co-founder of vVARDIS. "With this support, we're
able to accelerate a ground-breaking, transformational innovation towards
non-invasive, early-intervention dental care similar to the advancements that
medicine embraced years ago. As dentists, we are delighted to bring forward
the first non-invasive treatment for early-stage cavities through in-depth
restoration of lost minerals - a restorative treatment without artificial
materials - that promises to elevate the standard of care for patients around
the world."
With more than 25 years of science, vVARDIS' Curodont™ is backed by
universities internationally and has earned the endorsement of renowned
thought leaders, clinical experts, and innovators across the dental
profession. Dr. German O. Gallucci, Chair of the Department of Restorative
Dentistry and Biomaterials Sciences at Harvard School of Dental Medicine,
said, "Curodont™ is highly effective for treatment of early decays. This new
non-invasive therapeutic option is a game changer in the battle against tooth
decay."
At the conference, vVARDIS' founders Drs. Haley & Goly Abivardi also
initiated a new global public health awareness campaign addressing the
widespread and under-recognized global cavity crisis. Launched under the name
"Save Teeth Save Lives" and symbolized by a turquoise ribbon, the initiative
highlights the strong link between oral health and overall health and aims to
drive greater awareness for earlier intervention and non-invasive approaches
to the treatment of cavities worldwide.
The presence of cavities is the most prevalent
(https://www.who.int/news-room/fact-sheets/detail/sugars-and-dental-caries)
non-communicable disease worldwide and the most widespread
(https://pmc.ncbi.nlm.nih.gov/articles/PMC6373711/#:~:text=PREVALENCE%20OF%20TOOTH%20DECAY,experience%20various%20barriers%20to%20care.)
health issue in the U.S., affecting nearly 90 percent
(https://www.nidcr.nih.gov/research/data-statistics/dental-caries/adults) of
adults aged 20 to 64. It is also the most common chronic childhood disease,
with about 52 percent of children
(https://www.nidcr.nih.gov/research/data-statistics/dental-caries/children?utm_source=chatgpt.com)
having experienced a cavity in their baby teeth by age 8. Despite its
prevalence across all demographic groups, cavities disproportionately impact
vulnerable populations, including children and low-income communities; they
contribute to serious and costly chronic conditions such as heart disease, and
if left untreated, can lead to a 26 percent increased risk
(https://pmc.ncbi.nlm.nih.gov/articles/PMC9365626/) of all-cause
mortality 3 . Only in the U.S., 32 million school hours and 92 million work
hours (https://www.cdc.gov/oral-health/about/index.html) are lost annually
due to unplanned and emergency cavity treatments. The progression from
early-stage decay to bigger cavities can be rapid, especially in children, but
there is a critical window to halt this process and even restore tooth health
throughout the depth of the early cavities with Curodont™.
Drs. Abivardi wore and distributed the ribbons throughout the conference,
inviting attendees to join the movement and raise awareness about this
overlooked epidemic. Through early intervention, fear-free and drill-free
treatments, the awareness campaign supports lifelong oral health, dignity, and
well-being.
vVARDIS' innovation has been recognized by Dental Advisor, which just named
the company 2026 Innovative Company of the Year. Additionally, Curodont™
Repair Fluoride Plus received the Research Award which is a recognition of
vVARDIS' commitment to science-driven solutions that empower dental
professionals to enhance patient care and outcomes.
vVARDIS' momentum has been fueled by $85 million in funding from OrbiMed and
an expanded partnership with Henry Schein, helping to accelerate the company's
growth across North America. Today, Curodont™ is being rapidly adopted by
dental practices and is now available in nearly 12 percent of dental offices
in the U.S., including leading DSOs such as Aspen Dental and Heartland Dental.
Curodont™ is transforming oral care standards and addressing an over $30
billion opportunity in oral health in the U.S. market.
The Abivardi sisters are available for interviews throughout the conference to
discuss the science behind Curodont™, their journey as founders, the
importance of public health advocacy, and the significance of Jamie Dimon's
recognition for the future of dental innovation.
Media Contact:
Stephanie Blank
Stephanie.blank@fgsglobal.com (mailto:Stephanie.blank@fgsglobal.com)
917-593-2907
About vVARDIS AG
vVARDIS is a disruptive high-growth Swiss healthcare company located in Zug,
Switzerland that offers groundbreaking biomimetic, non-invasive solutions for
dental professionals under the Curodont™ brand. Founded by Drs. Haley and
Goly Abivardi, sisters, Swiss dentists, innovators, and awarded entrepreneurs,
vVARDIS is the result of more than 25 years of research, paired with the
commitment of its founders to make an impact on people's lives, especially the
underserved.
vVARDIS' mission is to expand access to novel approaches to the standard of
care in dentistry with the purpose of improving oral health - the foundation
for overall health. vVARDIS is backed by more than 25 years of science, 230
scientific publications, including meta-analysis, peer-reviewed clinical
studies and a long-term peer-reviewed real-world evidence study demonstrating
a success rate above 90 percent. It has been used in clinical practice for
more than 10 years. Curodont™ is already mentioned in lectures at renowned
universities as a standard of care for the treatment of early cavities.
vVARDIS is a member of the WEF Innovator Communities.
For more information, visit vVARDIS at www.vVARDIS.com
(http://www.vvardis.com/) and www.linkedin.com/company/vvardis
(http://www.linkedin.com/company/vvardis) .
About Curodont™
Using a proprietary biomimetic formulation, Curodont™ is a groundbreaking
drill-free, needle-free treatment for early cavities. Working together with
minerals in the saliva, Curodont treats the early cavities by hydroxyapatite
generation throughout the depth of the lesion. Curodont™ is fast and easy to
apply by a dental professional: once the formula is applied, it disperses
through the enamel and repairs the missing parts of the tooth (lesions) with
minerals from saliva by mimicking the way nature created teeth (biomimetic).
The beauty of this product is that Curodont™ helps patients save the natural
tooth structure without artificial filling materials.
# # #
( 1 ) Data on file
( 2
(file://///Users/gerhardpieldner/Library/Containers/com.microsoft.Outlook/Data/tmp/Outlook%20Temp/2258684-1768239301-EN_6665374661544688930.html#_ftnref2)
) vVARDIS' ranked first in growth rate in the 2024 vs 2023 and YTD June 2025
periods among dental manufacturers with more than $1M sales in both the all
merchandise & small equipment categories and preventive (Source: SDM
Northcoast, LLC).
( 3 ) Liu J et al. Int J Epidemiol. 2022;51:1291-1303
End of Media Release
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRABTMPTMTTBBLF
Copyright 2019 Regulatory News Service, all rights reserved